This week, biosimilar developer Coherus announced that it has resubmitted a Biologics License Application (BLA) for CHS-1701, a pegfilgrastim biosimilar candidate referencing Neulasta.
This week, biosimilar developer Coherus announced that it has resubmitted a Biologics License Application (BLA) for CHS-1701, a pegfilgrastim biosimilar candidate referencing Neulasta.
“The CHS-1701 BLA resubmission marks a significant milestone in our ongoing transition to a commercial company as we tightly focus on execution of our strategic plan. Pegfilgrastim is the largest selling oncology product in the [United States], and CHS-1701 is the cornerstone of our oncology franchise. We believe we have a strong competitive position with this product, exemplified by our comprehensive clinical immunogenicity data as well as our excellent analytical biosimilarity data,” said Denny Lanfear, president and CEO of Coherus Biosciences in a statement to investors.
In June 2017, Coherus announced that the FDA had issued a Complete Response Letter (CRL) for its proposed pegfilgrastim biosimilar, requesting that the company perform a reanalysis of a subset of samples with a revised immunogenicity assay as well as additional manufacturing information.
The newly submitted BLA is supported by data from analytical, pharmacokinetic, pharmacodynamics, and immunogenicity studies comparing CHS-1701 with the reference product. The updated application also integrates the requested immunogenicity data requested by the FDA.
This resubmission is the latest in a streak of good news for Coherus’ pegfilgrastim candidate. In March, a Delaware court judge granted Coherus’ motion to dismiss a lawsuit brought by Amgen over alleged infringement of a patent covering the reference pegfilgrastim. The patent that was disputed, US patent 8,273,707, covered a process for purifying proteins during which 2 specific salts are used in a loading solution.
According to the court, Amgen previously acknowledged that Coherus did not “literally infringe” on the patent, and “the facts in the prosecution history here are undisputed.”
The company hopes to launch the biosimilar in the US market by mid-2018 and is also anticipating approval for the drug from the European Medicines Agency in the second half of this year.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.